Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 19Liver Neoplasms 2Cholangiocarcinoma 2Carcinoma 2Recurrence 1Pancreatic Neoplasms 1Locally Advanced Thyroid Gland Carcinoma 1Hepatocellular Carcinoma with PVTT 1Digestive System Neoplasms 1Diabetes Mellitus 1Cirrhosis, Familial, with Pulmonary Hypertension 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Carcinoma 1Biliary Tract Adenocarcinoma 1Biliary Malignant Tumors 1

Interventions

lenvatinib 3Surgical Procedures, Operative 3Fluorouracil 3Drug Therapy 3Oxaliplatin 2Leucovorin 2Gemcitabine 2Folfox protocol 2regorafenib 1gemcitabine-oxaliplatin regimen 1durvalumab 1donafenib 1apatinib 1Radiotherapy 1Hepatectomy 1Floxuridine 1Cryosurgery 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cirrhosis, Familial, with Pulmonary Hypertension × donafenib × Clear all
NCT07353827 2026-01-20

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Sun Yat-sen University

Phase 2 Not yet recruiting
36 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡